Cargando…

SUN-446 Association between Prolactin Level and Tumor Size Reduction at 3 Months after Cabergoline Treatment in Patients with Macroprolactinoma

Objectives: Prolactin (PRL) normalization after 3 months of Cabergoline (CAB) treatment are useful predictors of responsiveness in patients with prolactinoma. However, differences within the PRL normalization cut-off value have not been identified. Methods: We reviewed the medical records of patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Daham, Park, Kyeong Hye, Ku, Cheol Ryong, Shin, Dong Yeob, Lee, Eun Jig
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Endocrine Society 2019
Materias:	Neuroendocrinology and Pituitary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552842/ http://dx.doi.org/10.1210/js.2019-SUN-446

Ejemplares similares

MON-LB080 Change of T2-Weighted Intensity of Prolactinoma as a Predictable Value for Relapse of Hyperprolactinemia after Cabergoline Withdrawal
por: Kim, Kyungwon, et al.
Publicado: (2019)

SAT-LB47 Tension Pneumothorax Following Cabergoline Initiation for Macroprolactinoma
por: Go, Muriel Tania, et al.
Publicado: (2020)

SAT-275 Bitemporal Hemianopia as a Result of Cabergoline Therapy for Macroprolactinoma
por: Díaz-Balzac, Carlos A, et al.
Publicado: (2020)

ODP299 Cabergoline Administration Markedly Improves Cognitive Impairment Associated with Macroprolactinoma
por: Hoang, Thanh, et al.
Publicado: (2022)

FRI301 Prolactin And Obesity: Analysis Off Weight Oscillation In The Follow-up Of Macroprolactinomas
por: Oliveira, Miriam C, et al.
Publicado: (2023)

SUN-449 Medical versus Surgical Treatment of Macroprolactinomas (MP): Indications, Efficacy, and Safety
por: Cuccia, Mariela, et al.
Publicado: (2019)

MON-LB60 Prolactin Response to Metformin in Cabergoline-Resistant Prolactinomas: A Prospective Study
por: Corrêa Portari, Luiz Henrique, et al.
Publicado: (2020)

SUN-444 Efficacy and Safety of Dopamine Agonists in Psychiatric Patients Treated with Antipsychotics and Presenting a Macroprolactinoma
por: Allard, Lucie, et al.
Publicado: (2019)

SAT-436 Adjuvant Therapeutic Modalities in Acromegaly: Clinical Course and Factors Predicting Biochemical Controls
por: Jung, Hyein, et al.
Publicado: (2019)

MON-436 Clinical Phenotypes of GNAS Gene Mutations in Acromegalic Patients
por: Jung, Hyein, et al.
Publicado: (2019)

SUN-445 A Brazilian Multicentric Study Evaluating Pregnancies Induced by Cabergoline in Patients Harboring Prolactinomas
por: Sant Anna, Beatriz, et al.
Publicado: (2019)

Early Prediction of Long-Term Response to Cabergoline in Patients with Macroprolactinomas
por: Lee, Youngki, et al.
Publicado: (2014)

FRI322 Lack Of Tumor Size Change With Long-term Cabergoline For Prolactinoma
por: Bendaram, Snigdha Reddy, et al.
Publicado: (2023)

A Challenging Case of Pituitary Macroprolactinoma During Pregnancy
por: Zainal, Abir, et al.
Publicado: (2021)

Macroprolactinoma in a Patient With Schizophrenia: A Therapeutic Challenge
por: Voelz, Eduardo, et al.
Publicado: (2021)

SAT-477 Pituitary Carcinoma Arising from a Macroprolactinoma
por: Gammoh, Emily, et al.
Publicado: (2019)

SAT-258 Surprising Transformation of a Microprolactinoma to a Macroprolactinoma
por: Athonvarangkul, Diana, et al.
Publicado: (2020)

SAT-270 Priapism Secondary to Cabergoline
por: Amir, Maryam, et al.
Publicado: (2020)

SAT-260 Resolution of a Cystic Macroprolactinoma with Dopamine Agonist Therapy
por: Ansari, Mohammad Jamal Uddin, et al.
Publicado: (2020)

PMON121 GALACTORRHEA, MACROPROLACTINOMA IN A 53-YEAR-OLD MALE
por: Selman-Geara, Antonio, et al.
Publicado: (2022)

THU072 Association Between Nonalcoholic Fatty Liver Disease And Growth Hormone Deficiency In Patients With Nonfunctioning Pituitary Adenoma
por: Hwang, Yoon-a, et al.
Publicado: (2023)

MON-446 Glucocorticoids in Hair, Fingernail, and Blood as Biomarkers of Systemic Exposure
por: Davison, Belinda, et al.
Publicado: (2019)

PMON120 Clinical Course Of Untreated Giant Invasive Macroprolactinomas- A Case Series
por: Aung, Ei Thuzar, et al.
Publicado: (2022)

Treatment of Postsurgical Clinically Nonfunctioning Pituitary Adenomas Remnants With Cabergoline
por: Vieira, Marina C M, et al.
Publicado: (2021)

Discordance Between Prolactinoma Size and Prolactin Level: An Unusual Laboratory Finding
por: Dawaher, Wafa, et al.
Publicado: (2021)

SAT-278 Vaginal Cabergoline: A Simple Solution to a Challenging Problem
por: Abuaisha, Munder, et al.
Publicado: (2020)

SAT-272 Pituitary Macroadenoma Co-Secreting TSH and PRL Responsive to Cabergoline
por: Tirumalasetty, Saritha, et al.
Publicado: (2020)

FRI317 Simultaneous Occurrence Of A Pineal Germ Cell Tumor And Pituitary Macroprolactinoma In A Young Male
por: Monsour, Elio Paul, et al.
Publicado: (2023)

SAT347 Surprising Turn Of Events In A Patient With Weight Gain: Simultaneous Diagnosis Of Macroprolactinoma And Polycystic Ovary Syndrome
por: Keskinkilic, Ayse Nur, et al.
Publicado: (2023)

SAT-474 Giant Prolactinoma Case Series Assessing Response on Initial Dose of Cabergoline
por: Madan Paramasivan, Ameena, et al.
Publicado: (2019)

SAT-475 PRL Secreting Macroadenoma and Development CSF Leak Secondary to Cabergoline Use
por: Ulrich, Jenna, et al.
Publicado: (2019)

SAT-246 A Case of Cabergoline Induced Pituitary Apoplexy in a Patient with Prolactinoma
por: Ahuja, Ashim
Publicado: (2020)

MON-312 The Effects of Cabergoline in Pre-Surgical and Recurrence Periods of Cushing’s Disease Patients
por: Pereira, Ana Julia Garcia, et al.
Publicado: (2020)

PMON170 Treating human primary non-functioning pituitary adenoma cells with cabergoline
por: Begalli, Federica, et al.
Publicado: (2022)

FRI321 Aggressive Prolactinoma Empirically Treated With Cabergoline Leading To Rapid CSF Leak
por: Yau, Alice, et al.
Publicado: (2023)

Efficacy and Cerebrospinal Fluid Rhinorrhea after Cabergoline Treatment in Patients with Bioactive Macroprolactinoma
por: Kim, Hae-Kyung, et al.
Publicado: (2021)

SAT-446 No Central Adrenal Insufficiency Found in Adults with Prader-Willi Syndrome Tested by Multiple-Dose Metyrapone Test
por: Davidse, Kirsten, et al.
Publicado: (2019)

FRI298 Serum Prolactin To Tumor Size Ratio As An Effective Parameter To Accurately Distinguish Prolactinoma From NFPT
por: Mishra, Ipsita, et al.
Publicado: (2023)

MON-LB49 Atypical Presentation for a 5.5-cm Macroprolactinoma: Unilateral Visual Loss and Only Partial Hypopituitarism; Asymptomatic Hypogonadism
por: panjawatanan, panadeekarn, et al.
Publicado: (2020)

Addition of Cabergoline to Oral Octreotide Capsules May Improve Biochemical Control in Patients With Acromegaly Who Are Inadequately Controlled With Monotherapy
por: Fleseriu, Maria, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sdfe0guhg0lqo26fguptkh8ggs